Rep. Marjorie Taylor Greene Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Representative Marjorie Taylor Greene purchased shares of Novo Nordisk A/S valued between $15,001 and $50,000 on August 19th, as disclosed in a filing on August 20th.
• Novo Nordisk's stock has shown a 12-month range with a low of $45.05 and a high of $139.74, and the company recently reported $0.97 earnings per share, exceeding estimates.
• The firm plans to pay a semi-annual dividend of $0.4119 per share to shareholders of record on August 18th, representing a yield of 240.0% with a payout ratio of 22.53%.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 20th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on August 19th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of Palantir Technologies NASDAQ: PLTR on 7/15/2025.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 6/17/2025.
• Sold $1,001 - $15,000 in shares of lululemon athletica NASDAQ: LULU on 6/17/2025.
• Purchased $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 6/6/2025.
• Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 6/6/2025.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $55.4580 on Friday. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $139.74. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a 50-day moving average price of $63.03 and a 200-day moving average price of $69.62. The firm has a market capitalization of $247.62 billion, a PE ratio of 15.24, a price-to-earnings-growth ratio of 1.89 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is 22.53%.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent research reports. Hsbc Global Res downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 31st. BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective on the stock in a research note on Wednesday, August 13th. TD Cowen cut their price objective on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a report on Tuesday. BNP Paribas upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. Finally, Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Three analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $81.00.

Institutional Investors Weigh In On Novo Nordisk A/S

Institutional investors have recently added to or reduced their stakes in the business. North Star Investment Management Corp. lifted its holdings in Novo Nordisk A/S by 18.2% in the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after acquiring an additional 3,200 shares during the period. Bank of New York Mellon Corp grew its position in shares of Novo Nordisk A/S by 6.0% during the 1st quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company's stock valued at $58,316,000 after acquiring an additional 47,804 shares during the period. Stanley Laman Group Ltd. purchased a new position in Novo Nordisk A/S during the first quarter worth approximately $390,000. Dover Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $505,000. Finally, GAMMA Investing LLC lifted its position in shares of Novo Nordisk A/S by 9.6% during the 1st quarter. GAMMA Investing LLC now owns 9,466 shares of the company's stock valued at $657,000 after buying an additional 827 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.